{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:00Z","timestamp":1758845880539,"version":"3.44.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"DOI":"10.7759\/cureus.93184","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:49:53Z","timestamp":1758804593000},"source":"Crossref","is-referenced-by-count":0,"title":["Faith, Cancer, and Compromise: Managing Acute Myeloid Leukemia and Metastatic Triple-Negative Breast Cancer in a Jehovah's Witness Patient"],"prefix":"10.7759","author":[{"given":"Andy","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parima","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aye M","family":"Thida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armine","family":"Bagdasaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordonna","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"American Cancer Society. Key statistics for acute myeloid leukemia (AML). (2025). Accessed: April 27, 2025: https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html."},{"key":"ref2","unstructured":"National Cancer Institute. Cancer stat facts: leukemia \u2014 acute myeloid leukemia (AML). (2025). Accessed: April 27, 2025: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil E","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016, 374:2209-21. 10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson G","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, et al.. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009, 113:4179-87. 10.1182\/blood-2008-07-172007","journal-title":"Blood"},{"key":"ref6","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia, version 3.2023. (2025). Accessed: April 27, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"ref7","article-title":"Acute myeloid leukemia","author":"Vakiti A","year":"2024","unstructured":"Vakiti A, Reynolds SB, Mewawalla P. Acute myeloid leukemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum FR","year":"2017","unstructured":"Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017, 130:2373-83. 10.1182\/blood-2017-09-797712","journal-title":"Blood"},{"key":"ref9","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia, version 3.2019. (2025). Accessed: April 27, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07018","article-title":"Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia","volume":"85","author":"Fujisawa S","year":"2007","unstructured":"Fujisawa S, Naito K, Matsuoka T, Kobayashi M. Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia. Int J Hematol. 2007, 85:418-20. 10.1532\/IJH97.07018","journal-title":"Int J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25916","article-title":"Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia","volume":"95","author":"Bock AM","year":"2020","unstructured":"Bock AM, Pollyea DA. Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia. Am J Hematol. 2020, 95:E269-72. 10.1002\/ajh.25916","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2016.05.003","article-title":"A clinical challenge: treatment of acute myeloid leukemia in a Jehovah's Witness","volume":"38","author":"C\u00e1rdenas-Araujo D","year":"2016","unstructured":"C\u00e1rdenas-Araujo D, Gonz\u00e1lez-L\u00f3pez EE, Gonz\u00e1lez-Leal XJ, Jaime-P\u00e9rez JC, G\u00f3mez-Almaguer D. A clinical challenge: treatment of acute myeloid leukemia in a Jehovah's Witness. Rev Bras Hematol Hemoter. 2016, 38:358-60. 10.1016\/j.bjhh.2016.05.003","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2005.00611.x","article-title":"Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin","volume":"15","author":"Bareford D","year":"2005","unstructured":"Bareford D, Odeh B, Narayanan S, Wiltshire S. Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med. 2005, 15:445-8. 10.1111\/j.1365-3148.2005.00611.x","journal-title":"Transfus Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ph9010012","article-title":"Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah\u2019s Witness with mutant IDH1\/NPM1\/NRAS acute myeloid leukemia","volume":"9","author":"Emadi A","year":"2016","unstructured":"Emadi A, Bade NA, Stevenson B, Singh Z. Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah\u2019s Witness with mutant IDH1\/NPM1\/NRAS acute myeloid leukemia. Pharmaceuticals (Basel). 2016, 9:10.3390\/ph9010012","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376992-faith-cancer-and-compromise-managing-acute-myeloid-leukemia-and-metastatic-triple-negative-breast-cancer-in-a-jehovahs-witness-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:49:55Z","timestamp":1758804595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376992-faith-cancer-and-compromise-managing-acute-myeloid-leukemia-and-metastatic-triple-negative-breast-cancer-in-a-jehovahs-witness-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.93184","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}